Effect of Intrinsic and Extrinsic Factors on the Clinical Pharmacokinetics and Pharmacodynamics of Prasugrel
David S. Small(Eli Lilly (United States)), Daniel E. Salazar(Daiichi Sankyo (United States)), Christopher D. Payne(Eli Lilly (United States)), Christopher S. Konkoy(Eli Lilly (United States)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Kenneth J. Winters(Eli Lilly (United States)), Nagy A. Farid(Eli Lilly (United States))
Cited by 61
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617